SecBot SecBot
PRESS-RELEASE ·Filed Aug 29, 2026

CYTK

Cytokinetics, Incorporated
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The expanded efficacy data across both obstructive and non-obstructive HCM strengthens the case for aficamten as a potential standard-of-care for the full HCM spectrum, with the nHCM sNDA submission expected Q4 2026. Traders should watch for FDA acceptance and priority review designation. CYTK has a $10.8B market cap with 89% analyst buy ratings, consensus is already bullish, so a high-impact approval may already be partially priced in.

DirectionBullish
Confidencehigh
Horizonweeks

MYQORZO

▲ Bullish Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
Next catalyst
None dated

What to watchThe FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$70.91
T+0 close · Aug 29, 2026 · via day close
Latest settled
−7.43%
T+20 · $65.64 · next T+60 in 7d
Vs SPY
−7.06%
α at T+20
Latest observation
−15.38%
T+53 · FF3 residual α
  1. T+0 · Aug 31 $70.91entry
  2. T+1 · 3mo ago +0.69%α +1.38% · $71.40
  3. T+5 · 2mo ago +6.26%α +6.40% · $75.35
  4. T+20 · 7w ago −7.43%α −7.06% · $65.64
  5. T+54 · todayOpen
  6. T+60 · in 7d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cytokinetics presented positive additional Phase 3 results at ESC 2026 showing aficamten (MYQORZO) improves cardiac structure and diastolic function in non-obstructive HCM and outperforms metoprolol across pre-trial treatment groups in obstructive HCM. The company plans to submit a supplemental NDA for the nHCM indication in Q4 2026, expanding the drug's potential addressable market beyond the currently approved oHCM population.

Key Facts

  • Additional ACACIA-HCM results showed aficamten significantly improved diastolic function (peak E velocity, septal e' velocity) and reduced left ventricular wall thickness (-0.2 cm, p<0.001) in nHCM at up to 72 weeks.
  • MAPLE-HCM post-hoc analysis showed aficamten improved pVO2 vs metoprolol irrespective of prior beta-blocker use (no beta blockers: +3.1 mL/kg/min, p<0.001; on beta blockers: +1.9 mL/kg/min, p<0.001).
  • Cytokinetics plans to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026.

Financial Impact

Expansion of aficamten's addressable market to ~50% of HCM patients (nHCM) who currently have no approved therapies; sNDA submission Q4 2026

revenuemarket accesspipeline value

Risk Factors

  • FDA could issue a Complete Response Letter or require additional trials for nHCM, delaying or denying approval.
  • Competition from existing therapies (mavacamten/camzyos) and other emerging HCM drugs could limit market share.
  • Aficamten's boxed warning for heart failure risk and REMS program may limit uptake in broader nHCM population.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3352934

Track record

46 reports on CYTK

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $56.13 +4.41% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $56.13 +0.00% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $56.13 +1.04% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $56.13 −11.75% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $56.13 −9.51% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (11h 58m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 29, 2026